In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Candesartan cilexetil, Atacand, Amias, Blopress, Ratacand, TCV 116, TCY 116 Drug Master File in Korea (Candesartan cilexetil, Atacand, Amias, Blopress, Ratacand, TCV 116, TCY 116 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Candesartan cilexetil, Atacand, Amias, Blopress, Ratacand, TCV 116, TCY 116. The MFDS reviews the Candesartan cilexetil, Atacand, Amias, Blopress, Ratacand, TCV 116, TCY 116 KDMF as part of the drug registration process and uses the information provided in the Candesartan cilexetil, Atacand, Amias, Blopress, Ratacand, TCV 116, TCY 116 KDMF to evaluate the safety and efficacy of the drug.
After submitting a Candesartan cilexetil, Atacand, Amias, Blopress, Ratacand, TCV 116, TCY 116 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Candesartan cilexetil, Atacand, Amias, Blopress, Ratacand, TCV 116, TCY 116 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Candesartan cilexetil, Atacand, Amias, Blopress, Ratacand, TCV 116, TCY 116 suppliers with KDMF on PharmaCompass.